FDA ANDA · ANDA205063
ISOTRETINOIN
Sponsor: ACTAVIS LABS FL
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
ANDA205063
TYPE
ANDA
ORIGINAL APPROVAL
2021-03-31
LATEST ACTION
2026-10-07
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription
Products
ISOTRETINOINPrescription
ISOTRETINOIN 40MG · CAPSULE · ORAL
ISOTRETINOINPrescription
ISOTRETINOIN 30MG · CAPSULE · ORAL
ISOTRETINOINPrescription
ISOTRETINOIN 20MG · CAPSULE · ORAL
ISOTRETINOINPrescription
ISOTRETINOIN 35MG · CAPSULE · ORAL
ISOTRETINOINPrescription
ISOTRETINOIN 25MG · CAPSULE · ORAL
ISOTRETINOINPrescription
ISOTRETINOIN 10MG · CAPSULE · ORAL
Approval history
2026-10-07REMS · Supplement 13AP
2026-02-09REMS · Supplement 10AP
2025-06-18Labeling · Supplement 11 · standardAP
2025-06-03Labeling · Supplement 8 · standardAP
2023-03-24REMS · Supplement 5AP
2022-10-06REMS · Supplement 4AP
2021-10-08REMS · Supplement 1AP
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →